Issue No. 50, Jan 2026Electronic ISSN 2521-3881 |
||
| Issue No. 50 - Jan2026 | ||
| 7-18 | The impact of mental toughness training program on psychological well-being and resilience in cancer patients: A Randomized Controlled Trial | |
|
Negin Hemmati,1 Kourosh Zarea,2 Samira Beiranvand,3 Saeed Ghanbari,4 Mehran Hosseinzadeh5 1 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 2 Nursing Care Research Center in Chronic Diseases, Nursing and Midwifery School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 3 Nursing Care Research Center in Chronic Diseases, Nursing and Midwifery School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 4 Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 5 Hematology, Oncology Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran | ||
| Abstract | ||
|
Purpose : This study aims to investigate the effects of a mental toughness education program on the psychological well-being and resilience of cancer patients.
Method: This randomized clinical trial recruited 32 adults with cancer from Baqayi Hospital 2 in Ahvaz. The participants were divided into two groups: an intervention group and a control group. The intervention group received the psychological resilience-based educational intervention. Data were collected using four questionnaires, including the Ryff Psychological Well- Being Scale, the Connor-Davidson Resilience Scale, and the Clough Mental Toughness Scale. Data analysis was performed using SPSS software version 25.
Results: The average age of the participants in this study was 46.47 ± 10.21 years. The mean mental toughness scores before the intervention were 120.5 and 110.81 in the intervention and control groups, respectively. After the intervention, the mean scores increased to 164 and 111.88, respectively, and this difference was statistically significant (P<0.001). The overall mean resilience scores before and after the intervention in the intervention group were 49.56 and 108.63, respectively, with a statistically significant difference (P<0.001). The overall psychological well-being score decreased immediately after the intervention but increased one month later. However, this change was not statistically significant.
Conclusion: Based on the results of this study, psychological resilience education has a positive impact on resilience, psychological well-being, and certain dimensions of social well-being in patients with cancer. Therefore, interventions focused on developing psychological resilience, with an emphasis on increasing resilience and psychological well-being, can lead to positive outcomes in patients with cancer.
Keywords: Mental toughness, psychological resilience, cancer, psychological well-being, resilience.
|
||
| full article | ||
| 2 | 19-27 |
Neuro-oncology Burden in Developing Countries:A Retrospective Cost-Analysis Study |
|
Said Nassier Said Alsenani,1 Rawan Nasser Almaskari,1 Yusra Abid Shah,2 Balqees Yousuf Hussain Al Mujaini,3 Alshifa Khalifa Alsaidi,3 Maryam Saud Mohammed AlBalushi,4 Fatema Dawood Mulla Hasan Almualem,5 Tariq Al-Saadi6,7 1 The Medical City for Military & Security Services, Muscat, Sultanate of Oman 2 Sultan Qaboos University Hospital, Muscat, Sultanate of Oman 3 Sultan Qaboos University, Muscat, Sultanate of Oman 4 Oman Medical Specialty Board, OMSB emergency resident, Muscat, Sultanate of Oman 5 Ain Shams University Hospital, Cairo, Egypt 6 Department of Neurosurgery, Khoula Hospital, Muscat, P.O. Box-35, Postal Code 123, Sultanate of Oman. 7 Department of Neurosurgery – Cedars-Sinai Medical Centre, 8700 Beverly Blvd, Los Angeles, CA 90048 | ||
| Abstract | ||
|
Background: Brain tumours are a significant economic burden on patients and health systems.
Objectives: This research aims to study the cost associated with management of brain tumour and its impact on healthcare.
Methods and material: This is a retrospective observational study involving 280 patients with brain tumours at the Neurosurgery Department at Khoula Hospital in Oman. Data on patient demographics, type of brain tumour, diagnosis, treatment, cost of imaging and laboratory investigations, and length of hospital stay were collected from medical records.
Results: The average cost of imaging and laboratory investigations was $276,293.33, with imaging accounting for $208,168.7 and laboratory tests accounting for $68,124.63. CT scan was the most expensive imaging investigation, followed by MRI and X-ray. RFT, MDR, and MRSA screening were the most expensive laboratory tests. The most common diagnosis was meningioma (18% of cases). The average length of hospital stay was 16 days.
Conclusion: The cost of brain tumour management in Oman is significant. Further research is needed to understand the full economic burden of brain tumour management in Oman, including the costs of surgical and non-surgical interventions.
Keywords: brain tumour, cost analysis, neurosurgery, Leave against medical advice, LAMA, Discharge Against Medical Advice, DAMA.
|
||
| full article | ||
| 3 | 28-35 | Prospective observational comparative study of radiotherapy induced toxicities (xerostomia, skin reaction, and mucositis) between three-dimensional conformal radiotherapy and intensity modulated radiotherapy technique to oral cavity cancer of head and neck |
|
Dr. Mhendr Dhakar 1, Dr. Hameeduzzafar Ghori2, Dr. Atal Singh Parihar3, Dr. Raju Prajapati4, Dr. Om Prakash Singh5, Dr. Vineeta Yogi2, Dr. Vivek Tiwari2, Dr. Rakesh Mahawar6, Dr. Tushar Jassal7 1 Clearmedi Paridhi hospital, Gwalior, Madhya Pradesh, India 2 Gandhi Medical College and Hamidia Hospital, Bhopal, Madhya Pradesh, India 3 LHDM and Dr. Prem Hospital, Panipat, Haryana, India 4 Sukh Sagar Medical College and Hospital, Jabalpur, Madhya Pradesh, India 5 Mahaveer Institute of Medical science and research, Bhopal, Madhya Pradesh, India 6 Nidan Cancer Care Group, Bhopal, Madhya Pradesh, India 7 All India Institute of Medical Sciences (AIIMS), New Delhi, India | ||
| Abstract | ||
|
Background: Oral cavity cancers often require radiotherapy (RT), leading to toxicities such as xerostomia, skin reactions, and mucositis. This study aims to compare these toxicities between three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) techniques. Methods: This prospective observational study included 60 patients with primary oral cavity squamous cell carcinoma. Patients were divided into two groups: 30 underwent 3D-CRT, and 30 underwent IMRT. Toxicities were assessed weekly during RT and bi-monthly up to one year post-RT using Radiotherapy Oncology Group (RTOG) criteria. Results: The mean age was 46.60 ± 11.58 years for 3D-CRT and 48.0 ± 11.38 years for IMRT patients. Both groups had a majority of male patients. No significant difference was observed in mucositis and skin reactions. However, xerostomia was significantly higher in the 3D-CRT group from 6 to 10 months post-RT. Conclusion: IMRT is preferable for treating oral cavity cancer to reduce long-term xerostomia compared to 3D-CRT, despite similar rates of acute mucositis and skin reactions. Keywords: Radiotherapy; Oral cavity cancer; Xerostomia; Skin reaction; Mucositis; Three-dimensional conformal radiotherapy (3D-CRT); Intensity-modulated radiotherapy (IMRT)
|
||
| full article | ||
| 4 | 36-46 |
Epidemiological characteristics, prognostic factors, and survival of resectable colorectal cancer in a Moroccan population |
|
Rachid El Jim 1, Yousra. El Kirami 1, Laila. Chbani2, Hind. Mrabti3, Adil. Najdi 4, Karima. El Rhazi5, Naoufel. Mellas6, Ghizlane. Kharrasse7, Said. Afkir8, Khalid. Maazaz9, Mohammed. El Abkari1, Sidi Adil. Ibrahimi 1, Nada. Lahmidani1 1 Department of Gastroenterology, Faculty of Medicine, Pharmacy and Dentistry, Hassan II University Hospital, Fez, Morocco 2 Department of Anatomopathology, Hassan II University Hospital, Fez, Morocco 3 Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco. 4 Department of Epidemiology and Public Health, Faculty of Medicine and Pharmacy, Tangier, Morocco 5 Department of Epidemiology and Public Health, Faculty of Medicine, pharmacy and dentistry, Fez Morocco 6 Department of Medical Oncology, University Hospital Hassan II, Fez , Morocco 7 Department of Gastroenterology, Mohammed VI University Hospital, Oujda, Morocco 8 Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University, Oujda, Morocco. 9 Department of General Surgery B, University Hospital Hassan II, Fez, Morocco. | ||
| Abstract | ||
|
Introduction : Colorectal cancer is one of the most common digestive cancers worldwide and constitutes a major public health problem in Morocco, a country where its incidence is increasing. The majority of patients are often diagnosed at an advanced stage, which sometimes compromises the prognosis. This study aims to describe the epidemiological, clinical, and histopathological profile of colorectal adenocarcinomas in Morocco and to identify prognostic factors influencing survival. Materials and Methods: We conducted a prospective, descriptive, and analytical multicenter study between February 2015 and February 2021, including 214 patients with histologically confirmed colorectal adenocarcinoma, followed up in three Moroccan university hospitals (Fez, Oujda, and Rabat). Clinical, pathological, and therapeutic data were collected from medical records. Overall survival was estimated using the Kaplan-Meier method, and prognostic factors were evaluated using multivariate analysis. Results : The mean age of patients was 57 years (22-86 years), with a sex ratio of 1.02. Colonic forms accounted for 45.8% of cases, mostly located in the left colon, and rectal forms 33.2%, predominantly in the lower rectum. Significant complications were present in 21.5% of cases, primarily obstructions. Histologically, 52.3% of tumors were well differentiated, and 10.3% had a mucinous component. Curative resection was possible in 60.3% of cases. Overall survival was 82% at 1 year, 70.5% at 2 years, and 48.9% at 5 years. Factors associated with a poor prognosis were male gender, age <50 years, advanced tumor stage, the presence of a mucinous component, and the need for palliative treatment. Discussion: Consistent with global research, our results emphasize the prevalence of late-stage diagnoses and the detrimental effect of tumor complications on survival. Due to delayed presentation and limited early detection, the five-year survival rate is still lower than in Western nations. Poorer outcomes are linked to a mucinous component and a younger age at diagnosis, highlighting the importance of early intervention and focused screening. Conclusion: Colorectal cancer in Morocco is diagnosed late in nearly one-third of cases, with a major impact on survival. Management is based on a multidisciplinary approach integrating surgery, chemotherapy, and radiotherapy. The prognosis is significantly better for early-diagnosed forms undergoing surgery with R0 resection. Strengthening screening and improving access to care are essential to reduce CRC-related mortality in Morocco. Keywords: Colorectal cancer, Epidemiology, Survival, Prognostic factors, Treatment |
||
| full article | ||
| 5 | 47-55 | A Prospective Study Comparing Treatment Outcomes of Brentuximab Vedotin Plus AVD versus ABVD in Egyptian Patients with Advanced Classical Hodgkin Lymphoma |
|
Marwa N. Omar1, Zeinab M. Elsayed2, Rania M. Afify3, Nervana M. Hussien4,5, Haytham A. Abdelkader4,5 1 Assistant lecturer of Clinical Oncology Department, Faculty of Medicine, Helwan University, Helwan, Egypt. |
||
| Abstract | ||
|
Background : Classical Hodgkin lymphoma (cHL) is a malignancy that is readily amenable to treatment, but still advanced-stage disease (stage III/IV) carries a significant therapeutic challenge. While ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is a standard frontline regimen, its efficacy is limited by toxicity and relapse rates. Brentuximab Vedotin (BV), an anti-CD30 antibody-drug conjugate, concurrent with AVD (BV+AVD) has emerged as a promising alternative. This study compares the effectiveness and tolerability of BV+AVD versus ABVD in Egyptian patients with advanced cHL. Methodology : A prospective, randomized, open-label study was conducted at Helwan University Hospitals (March 2023-February 2025). A total of sixty patients with newly diagnosed stage III/IV cHL were randomized to receive either BV combined with AVD (BV+AVD; n = 30) or standard ABVD (n = 30). The primary endpoint was PFS, while secondary endpoints included PET negativity after two cycles, overall response rate (ORR), overall survival (OS), and treatment-related toxicity. Results : Interim analysis demonstrated superior 2-year PFS for BV+AVD (80.0%) versus ABVD (53.3%). BV+AVD showed higher PET negativity rates post-cycle 2 (83.3% vs. 76.6%) and reduced pulmonary toxicity (6.7% vs. 23.3%). Hematologic toxicity (neutropenia: 60% vs. 40%) and neuropathy (43.3% vs. 16.7%) were more frequent with BV+AVD but mainly low grade and manageable. Discussion : Limitations of this study encompass that it is a single-center study with a relatively small sample size that reduces the statistical power and makes it challenging to detect rare side effects. The population of the study represents the young and middle age group of patients with cHL so the treatment effect on older population was not studied. The limited follow-up duration restricts further knowledge about late relapses or delayed toxicities. Conclusion : BV+AVD significantly improves PFS and reduces bleomycin-associated toxicity, supporting its adoption as a frontline regimen for advanced cHL. Extended follow-up is required to validate the observed survival benefits. Keywords : Hodgkin Lymphoma, ABVD, Brentuximab Vedotin, AVD, PET/CT |
||
| full article | ||
| 6 | 56-64 | Factors Influencing Breast Cancer Survival Outcomes in the Central Region of Saudi Arabia |
|
Amen Bawazir1*, Sadeem Alhalafi2, Abdulrahman Jazieh3,4,5, Wasif Ali Khan1*, Rumaisa Ali Khan6 1 Department of Basic Medical Sciences, College of Medicine, Almaarefa University, Riyadh, KSA. |
||
| Abstract | ||
|
Background: Globally, breast cancer (BC) stands as the most common malignancy, predominantly affecting women, with observed trends of increasing incidence and mortality. Data concerning the survival of BC patients in Saudi Arabia (SA) is notably scarce. This study aims to pinpoint the specific factors that impact the survival rate (SR) among breast cancer patients in Saudi Arabia’s central region. Methods: This retrospective study analyzed data from 1405 breast cancer patients documented in the King Abdulaziz Medical City Cancer Registry from 2009 to 2018. The collected patient information included sociodemographic details and comprehensive tumor characteristics such as its location, histopathology, molecular subtypes, disease stage, and ultimate survival outcomes. To assess the relationship between these factors and patient survival, survival analyses were performed, incorporating Kaplan-Meier curves and Cox regression models, which were adjusted for potential confounding variables. Results: Patients of older age (over 60 years) demonstrated a higher mortality risk from breast cancer. Invasive ductal carcinoma was the most frequently observed histopathologic subtype; however, invasive lobular carcinoma was linked to an elevated death risk. Adjusted Hazard Ratios from Cox regression indicated that BC patients with metastasis were six times (AHR=6.3; 95%CI=4.6-8.7, p<0.001) more likely to face a higher death risk compared to those with localized or regional tumors. Furthermore, patients diagnosed with triple-negative tumors were associated with twice the risk of death compared to other subtypes (AHR=2.1; 95%CI=1.4-2.9, p<0.001). Conclusion: Both patient age and the presence of distant cancer spread are critical predictors of survival for breast cancer patients residing in central Saudi Arabia. Emphasizing early diagnosis, timely treatment, and consistent follow-up is essential for enhancing patient outcomes. Keywords: Survival rate, Breast cancer, Histopathologic types, Molecular subtypes, Metastasis, Saudi Arabia. |
||
| full article | ||
| 7 | 65-69 | Assessing the use of anti-PD-1/PD-L1 cancer therapies in the Middle-Eastern Country of Lebanon: a single-center study |
|
Reem El Hindi1, Salim Moussa1 1 Department of medical laboratory technology department, Faculty of health sciences, Beirut Arab University, Beirut-Lebanon |
||
| Abstract | ||
|
Background: Immunotherapy is an effective cancer treatment strategy. Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1, have demonstrated promising clinical outcomes. In Lebanon, a lower-middle-income country with a history of economic collapse, oncologists began prescribing ICI therapy despite its high cost and the lack of clear evidence regarding the pattern of ICI clinical outcomes in Lebanese patients. The current status of ICIs use in Lebanon remains unclear. Methods: This retrospective study involved cancer patients treated with programmed cell death-1 (PD-1/PD-L1) inhibitors at the Central Military Hospital in Beirut, Lebanon. Demographic and clinical data were collected from patients’ records from 2016 to 2024. Results: The study included 118 patients. The hospital covered the patient’s treatment. Of those, 59.3% (n = 70) had received ICIs. They were distributed as follows: 58.6% received pembrolizumab; 24.3%, nivolumab; and 17.2%, atezolizumab. Of the patients, approximately 35.7% (n = 25) had undergone a PD-L1 immunohistochemistry (IHC) test prior to receiving the ICI. All PD-L1-positive patients responded to ICI treatment: three showed no tumor progression and 11 showed tumor size regression. Conclusion: The study provided an overview of the use of ICIs at a single center in Lebanon. It revealed that ICI prescriptions were not consistently preceded by a PDL1 positivity test. A significant proportion of patients responded to ICIs, and no association was found between demographics, clinical variables, and clinical outcomes to ICIs. Keywords: Oncology; Immunotherapy; PD-1/PD-L1 Immune-checkpoint inhibitors; Middle-income country |
||
| full article | ||
| 8 | 70-86 | Review Article | Artificial Intelligence Applications in Prognosis and Treatment of Neuro-oncology: A review |
|
Adham Al-Rahbi1, Tariq Al-Habsi2, Tariq Al-Saadi3,4 1 Anatomical pathology program, Oman Medical Specialty Board, Al-khoudh, Muscat 132, Oman. |
||
| Abstract | ||
|
Introduction: Artificial intelligence (AI) is the general term that contains Machine Learning (ML), and Deep Learning (DL). Utilization of these technologies in brain tumor treatment and prognosis is promising. Aim: This article aims to review recent applications of AI in neuro-oncology treatment and prognosis. Furthermore, it elucidates the challenges and future directions. Method: A comprehensive literature review in four databases (Wiley, Scopus, PubMed, and Google Scholar) gave a total of 21 articles using AI in neuro-oncology treatment and disease prognosis. papers were grouped and reviewed. The data was summarized and presented in tables and graphs. This is the first article to review these two areas of AI in neuro-oncology in a single paper and provide insight into knowledge gaps and future directions. Results: Most of the reviewed articles are about prognosis (14 articles). The largest article in sample size (41222) is about the prediction of inpatient Length of Stay (LOS) after brain tumor surgery. They used twenty-nine machine learning algorithms. In articles about the treatment of neuro-oncology, the highest sample size is (1585) in assessment of treatment response using AI algorithms. Conclusion: AI technologies implementation in neuro-oncology is crucial. More research and validation of current applications is needed. And careful integration of these technologies is important. Keywords: Artificial intelligence (AI), Machine Learning (ML), Deep Learning (DL), Neuro-oncology, Neurosurgery, Treatment, Prognosis. |
||
| full article | ||
| 9 | 87-91 | Lower Gastrointestinal Bleeding Revealing an Early-Stage Primary Anorectal Melanoma: A Case Report |
|
Hanane Aksim1, Faisal El mouhafid2, Mohamed Kaakoua3, Meryem Belhamdiya1, Ismail Essadi3, Rachid El barni2, Rachid Akka1 1 Hepatogastroenterology Department, Military Hospital of Avicenne, Marrakech, Morocco |
||
| Abstract | ||
|
Introduction: Anorectal melanomas are rare and agressive malignant tumors of the anorectal region of the digestive tract. Due to their rarity and similarity to other more benign and common conditions, such as hemorrhoids, their diagnosis is often delayed, which worsens the prognosis of this aggressive disease. Histological evaluation with special immunohistochemical (IHC) staining is often essentiel to establish a confirmed diagnosis. In the localized stage, the primary treatment for this condition consists primarily of surgical resection combined with adjuvant immunotherapy. Case presentation: We report the case of a 62-year-old women who presented for an etiological evaluation of mild rectal bleeding without other associated signs. Proctological examination revealed the presence of a flashy mass occupying almost the entire anal lumen, with irregular thickening of the anterior anorectal wall during rectal examination. The colonoscopy revealed a friable and ulcerated process in the lower and middle rectum, and several biopsies were performed, confirming the diagnosis of rectal melanoma. The patient was successfully treated with surgery and adjuvant immunotherapy. Discussion/ conclusion: Our case demonstrates the importance of rapid diagnosis and a multidisciplinary therapeutic approach for a better prognosis of malignant rectal melanoma. Keywords: anorectal melanoma, rectal bleeding, immunohistochemistry, abdominoperineal resection. |
||
| full article | ||
| 10 | 92-95 | Case Report | Development of spontaneous subcutaneous emphysema in a case of squamous cell carcinoma of right lung during radiotherapy treatment a rare instance |
|
Dr Prarabdh Singh1, Dr Arjun Agarwal2, Dr Aditi Singh3, Dr Siddharth Arora4, Dr Kirti Arora5, Dr Ankit Tebrawal6 1 Assistant Professor, Department of Radiation Oncology, Rohilkhand Medical College and Hospital, Bareilly, Uttar Pradesh (India) |
||
| Abstract | ||
|
Introduction: Development of spontaneous subcutaneous emphysema is a rare and benign entity and in some cases it could be symptomatic. Subcutaneous emphysema is commonly seen in neck and chest wall which gradually extend to other body organs. It is characterised by development of neck swelling and chest pain with the involvement of deeper tissues of thoracic outlet chest and abdominal wall may predispose in life-threatening conditions. Case Presentation: We report a rare case report of a patient with advanced cancer of right lung who developed extensive subcutaneous emphysema during the course of treatment. Discussion/Conclusion: This case report highlights the possible etiology, treatment and outcomes of the same. Keywords: Subcutaneous emphysema (SE), Lung Cancer, Advanced stage |
||
| full article | ||